Company profile: Altimmune
1.1 - Company Overview
Company description
- Provider of vaccines and other biological products to address unmet market and public health needs, using proprietary non-invasive intranasal delivery to stimulate robust and durable immune responses for prevention; programs include pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for obesity and for metabolic dysfunction-associated steatohepatitis (MASH). Proof of principle shown in animals and initial human clinical studies.
Products and services
- Pemvidutide for MASH: An investigational GLP-1/glucagon dual receptor agonist engineered for treating metabolic dysfunction-associated steatohepatitis (MASH), addressing unmet public health needs
- Pemvidutide for Obesity: An investigational GLP-1/glucagon dual receptor agonist developed to treat obesity within Altimmune’s emerging biotechnology pipeline
- Proprietary Intranasal Delivery Technology: A proprietary platform enabling non-invasive intranasal delivery of vaccines and biological products, with proof-of-principle in animals and initial human studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Altimmune
Akarna Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development of novel small molecule therapeutics targeting inflammatory and fibrotic diseases, including a non-bile acid FXR agonist for nonalcoholic steatohepatitis (NASH), aiming to deliver best-in-class treatments for chronic liver diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akarna Therapeutics company profile →
Carmot Therapeutics
HQ: United States
Website
- Description: Provider of drug discovery and development for inflammatory, metabolic, and neurological diseases, leveraging its patented Chemotype Evolution platform to accelerate discovery of disease‑modifying therapies. Pipeline includes CT‑388 and CT‑868 (dual GLP‑1/GIP agonists), CT‑996 (oral GLP‑1 agonist) for obesity and type 1 diabetes, and CT‑PYY for Prader‑Willi syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carmot Therapeutics company profile →
XOMA
HQ: United States
Website
- Description: Provider of biotech royalty aggregation through acquiring economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies, supported by a royalty portfolio of licenses; also provider of antibody discovery and development via a phage display platform, with developing assets including ebopiprant and an anti-prolactin antibody.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XOMA company profile →
Inozyme Pharma
HQ: United States
Website
- Description: Provider of therapies for rare diseases of calcification affecting soft tissues and bone, including a clinical-stage enzyme therapy (INZ-701) for pathologic mineralization and intimal proliferation in ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. Conducts clinical trials, offers a genetic testing process for ENPP1 Deficiency, and provides patient and family support and community resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inozyme Pharma company profile →
NGM Bio
HQ: United States
Website
- Description: Provider of biotherapeutic drug discovery focused on the gastrointestinal endocrine system, developing: NGM707 (ILT2/ILT4 antagonist), NGM831 (ILT3 antagonist), NGM438 (LAIR1 antagonist) for advanced solid tumors; NGM120 (GFRAL antagonist) for advanced solid tumors and cachexia; NGM621 (anti-Complement C3) for geographic atrophy; aldafermin (FGF19 analog) for NASH F4 and primary sclerosing cholangitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NGM Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Altimmune
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Altimmune
2.2 - Growth funds investing in similar companies to Altimmune
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Altimmune
4.2 - Public trading comparable groups for Altimmune
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →